Difference between revisions of "Mesna (Mesnex)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
|||
| (11 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Detoxifying agent to reduce the risk of hemorrhagic cystitis with agents such as [[Ifosfamide (Ifex)]]. Mesna is rapidly metabolized to mesna disulfide (dimesna), which remains intravascular and is rapidly processed by the kidneys, where it is converted back into mesna. Mesna binds to the urotoxic metabolites of ifosfamide, acrolein and 4-hydroxy-ifosfamide, limiting the risk of hemorrhagic cystitis. It has not been shown to interfere with antitumor efficacy.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Prntlbl.pdf Mesna (Mesnex) package insert]</ref><ref>[ | + | Class/mechanism: Detoxifying agent to reduce the risk of hemorrhagic cystitis with agents such as [[Ifosfamide (Ifex)]]. Mesna is rapidly metabolized to mesna disulfide (dimesna), which remains intravascular and is rapidly processed by the kidneys, where it is converted back into mesna. Mesna binds to the urotoxic metabolites of ifosfamide, acrolein and 4-hydroxy-ifosfamide, limiting the risk of hemorrhagic cystitis. It has not been shown to interfere with antitumor efficacy.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Prntlbl.pdf Mesna (Mesnex) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/mesna.pdf Mesna (Mesnex) package insert (locally hosted backup)]</ref> |
<br>Route: IV, PO | <br>Route: IV, PO | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 20: | Line 10: | ||
*[http://chemocare.com/bio/mesna.asp Mesna (Mesnex) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/mesna.asp Mesna (Mesnex) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/mesna.asp Mesna (Mesnex) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/mesna.asp Mesna (Mesnex) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/mesna-patient-drug-information Mesna (Mesnex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/mesna-patient-drug-information Mesna (Mesnex) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/mesna-patient-drug-information Mesna (Mesnex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/mesna-patient-drug-information Mesna (Mesnex) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *1988-12-30: Initial FDA approval | ||
==Also known as== | ==Also known as== | ||
| − | Anti Uron | + | *'''Brand names:''' Anti Uron, Mesa, Mesnex, Mesnil, Mestian, Mistabron, Mistabronco, Mitexan, Mucolene, Neper, Novacarel, Siruta, Uromes, Uromitexan, Uroprot, Varimesna |
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:Oral medications]] | ||
| + | |||
| + | [[Category:Chemotherapy protective agents]] | ||
| + | |||
| + | [[Category:FDA approved in 1988]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 01:06, 29 June 2024
General information
Class/mechanism: Detoxifying agent to reduce the risk of hemorrhagic cystitis with agents such as Ifosfamide (Ifex). Mesna is rapidly metabolized to mesna disulfide (dimesna), which remains intravascular and is rapidly processed by the kidneys, where it is converted back into mesna. Mesna binds to the urotoxic metabolites of ifosfamide, acrolein and 4-hydroxy-ifosfamide, limiting the risk of hemorrhagic cystitis. It has not been shown to interfere with antitumor efficacy.[1][2]
Route: IV, PO
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Patient drug information
- Mesna (Mesnex) package insert PDF page 14-16[1]
- Mesna (Mesnex) patient drug information (Chemocare)[3]
- Mesna (Mesnex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1988-12-30: Initial FDA approval
Also known as
- Brand names: Anti Uron, Mesa, Mesnex, Mesnil, Mestian, Mistabron, Mistabronco, Mitexan, Mucolene, Neper, Novacarel, Siruta, Uromes, Uromitexan, Uroprot, Varimesna